Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918783 · ClinicalTrials.gov registry record · Phase 1
Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer
A Phase 1 study of Peripheral Lung Tumor, sponsored by Impact Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05918783: Recruiting Phase 1 study of Peripheral Lung Tumor, sponsored by Impact Biotech.
NCT05918783 is a Phase 1 study of Peripheral Lung Tumor that is actively recruiting participants, run by Impact Biotech. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05918783, a Phase 1 study of Peripheral Lung Tumor, is actively recruiting participants, sponsored by Impact Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure. Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.
Primary Outcome
Incidence of treatment-related adverse events as assessed by CTCAE v5.0
Conditions Studied
Interventions
- COMBINATION_PRODUCT Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
Study Locations (1)
Maryland
- Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-05-28 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 1 |
What NCT05918783 shows while recruiting
NCT05918783 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Peripheral Lung Tumor appearing as the primary indexed condition, and to 1 intervention - of which Padeliporfin Vascular Targeted Photodynamic (VTP) therapy is the first listed.
NCT05918783 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05918783 about?
NCT05918783 is a clinical study titled "Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer". Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days foll...
What is the current status of trial NCT05918783?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-05-28. Estimated completion is 2028-12-30.
What conditions does trial NCT05918783 study?
This clinical trial studies the following conditions: Peripheral Lung Tumor.
What interventions are being tested in trial NCT05918783?
The interventions under investigation include: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05918783?
This trial is sponsored by Impact Biotech, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918783 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05918783's enrollment target sits among peer trials
36 1211th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI